GlassScriptPhysician profile
Vincent Y Wang
NPI 1194737486
$21,495.06
in general payments reported to CMS, 2019-2025
60 companies · $2,368 in 2025
The $2,368 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,206 · 2020: $1,975 · 2021: $2,681 · 2022: $2,396 · 2023: $5,957 · 2024: $2,912 · 2025: $2,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,670 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,375 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,669.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,375.00 |
| Education | $192.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,551.04 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $4,126.31 | 2021-2025 | Creon, Ubrelvy, Qulipta |
| Gilead Sciences, INC. | $1,601.77 | 2019-2025 | |
| Novo Nordisk INC | $999.21 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $955.91 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $762.39 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $756.11 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $726.64 | 2019-2024 | Xifaxan, Trulance |
| Ibsa Pharma INC. | $609.36 | 2022-2024 | Licart, Tirosint, Licart |
| Amarin Pharma, INC. | $602.18 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $516.37 | 2019-2023 | Xarelto |
| Opko Pharmaceuticals, LLC | $371.86 | 2019-2025 | Rayaldee |
| Intra-Sana Laboratories | $360.23 | 2023-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Idorsia Pharmaceuticals US INC | $337.12 | 2022-2024 | Quviviq |
| Pfizer INC. | $314.84 | 2019-2025 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.